Inventor · disambiguated record
Manmohan Reddy Leleti
Also filed as: LELETI MANMOHAN R · LELETI MANMOHAN REDDY
69 granted patents·26 pending applications·407 citations·filing 2006–2024
99Inventor score
Top patents by PatentIndex Score
95 records- 0198US11001603B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2020·Granted May 11, 2021·13 cites·1 claims
- 0298US9834545B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2016·Granted Dec 5, 2017·26 cites·33 claims
- 0397US10035768B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2017·Granted Jul 31, 2018·23 cites·10 claims
- 0497US9809581B2Inhibitors of CXCR2CHEMOCENTRYX INC·Filed 2016·Granted Nov 7, 2017·23 cites·29 claims
- 0597US9573897B2C5AR antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Feb 21, 2017·24 cites·9 claims
- 0696US11633416B1Oral formulations of CD73 compoundsARCUS BIOSCIENCES INC·Filed 2021·Granted Apr 25, 2023·4 cites·24 claims
- 0796US10239912B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 26, 2019·23 cites·47 claims
- 0896US8906938B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2013·Granted Dec 9, 2014·28 cites·5 claims
- 0995US11667662B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2021·Granted Jun 6, 2023·4 cites·9 claims
- 1095US10981944B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2019·Granted Apr 20, 2021·11 cites·20 claims
- 1195US10660897B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2018·Granted May 26, 2020·6 cites·5 claims
- 1295US9126939B2C5AR antagonistsFAN PINGCHEN·Filed 2011·Granted Sep 8, 2015·30 cites·4 claims
- 1395US8445515B2C5aR antagonistsFAN PINGCHEN·Filed 2009·Granted May 21, 2013·38 cites·25 claims
- 1494US12168023B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Granted Dec 17, 2024·1 cites·24 claims
- 1594US11787762B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2022·Granted Oct 17, 2023·2 cites·26 claims
- 1694US11142521B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Oct 12, 2021·4 cites·6 claims
- 1794US10370363B2Inhibitors of CXCR2CHEMOCENTRYX INC·Filed 2017·Granted Aug 6, 2019·6 cites·13 claims
- 1894US10336736B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2017·Granted Jul 2, 2019·6 cites·24 claims
- 1993US11407712B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2αARCUS BIOSCIENCES INC·Filed 2021·Granted Aug 9, 2022·3 cites·15 claims
- 2093US7807704B2Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2CHEMOCENTRYX INC·Filed 2007·Granted Oct 5, 2010·30 cites·18 claims
- 2192US12145901B1Process for preparing tetralin compoundsARCUS BIOSCIENCES INC·Filed 2022·Granted Nov 19, 2024·2 cites·25 claims
- 2292US10399962B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Sep 3, 2019·13 cites·25 claims
- 2391US10988464B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2019·Granted Apr 27, 2021·3 cites·16 claims
- 2490US11040960B2Inhibitors of CXCR2CHEMOCENTRYX INC·Filed 2019·Granted Jun 22, 2021·3 cites·14 claims
- 2590US9758512B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2016·Granted Sep 12, 2017·6 cites·24 claims
- 2689US10759789B22-oxindole compoundsCHEMOCENTRYX INC·Filed 2019·Granted Sep 1, 2020·2 cites·27 claims
- 2789US10421748B22-oxindole compoundsCHEMOCENTRYX INC·Filed 2018·Granted Sep 24, 2019·3 cites·43 claims
- 2889US7777035B2Azaindazole compounds and methods of useCHEMOCENTRYX INC·Filed 2007·Granted Aug 17, 2010·9 cites·10 claims
- 2989US7524845B2Azaindazole compounds and methods of useCHEMOCENTRYX INC·Filed 2006·Granted Apr 28, 2009·15 cites·39 claims
- 3088US12195447B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2021·Granted Jan 14, 2025·1 cites·2 claims
- 3188US8835419B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2012·Granted Sep 16, 2014·9 cites·30 claims
- 3287US11072597B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2019·Granted Jul 27, 2021·3 cites·14 claims
- 3387US9567323B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2014·Granted Feb 14, 2017·6 cites·9 claims
- 3486US12459967B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Nov 4, 2025·0 cites·11 claims
- 3586US12103907B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2023·Granted Oct 1, 2024·0 cites·1 claims
- 3686US11434230B22-oxindole compoundsCHEMOCENTRYX INC·Filed 2020·Granted Sep 6, 2022·1 cites·14 claims
- 3786US10407417B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2017·Granted Sep 10, 2019·3 cites·12 claims
- 3885US11058704B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2017·Granted Jul 13, 2021·4 cites·25 claims
- 3984US2024299306A1Capsule formulationsCHEMOCENTRYX INC·Filed 2024·Application pending·0 cites
- 4083US12139475B22-oxindole compoundsCHEMOCENTRYX INC·Filed 2022·Granted Nov 12, 2024·0 cites·4 claims
- 4183US11603356B2Amorphous form of a complement component C5a receptorCHEMOCENTRYX INC·Filed 2020·Granted Mar 14, 2023·1 cites·43 claims
- 4283US2023102258A1C5ar antagonistsCHEMOCENTRYX INC·Filed 2022·Application pending·0 cites
- 4383US2025319113A1Inhibitors of adenosine 5'-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 4482US2025214930A1Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alphaARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 4581US9340509B2CCR6 compoundsCHEMOCENTRYX INC·Filed 2014·Granted May 17, 2016·4 cites·17 claims
- 4680US9795599B2CCR6 compoundsCHEMOCENTRYX INC·Filed 2016·Granted Oct 24, 2017·2 cites·24 claims
- 4780US9790204B2Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Oct 17, 2017·2 cites·38 claims
- 4879US11951214B2Capsule formulationsCHEMOCENTRYX INC·Filed 2021·Granted Apr 9, 2024·0 cites·18 claims
- 4979US11267845B2Inhibitors of CD73-mediated immunosuppressionARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 8, 2022·1 cites·32 claims
- 5079US11045472B2Quinazoline-pyridine derivatives for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Jun 29, 2021·1 cites·20 claims
Showing the top 50 of 95 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Manmohan Reddy Leleti files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →